Core Viewpoint - Jiahe Biotech-B (06998) has completed a proposed merger and plans to change its name to "Yiteng Jiahe Pharmaceutical Group Limited" effective December 31, 2024, marking a significant milestone as the first reverse acquisition case in Hong Kong's 18A sector [1] Group 1: Merger and Name Change - Jiahe Biotech has announced the completion of its proposed merger and will change its name to "Yiteng Jiahe Pharmaceutical Group Limited" [1] - The new name will be effective from December 31, 2024, and the company's shares will no longer carry the "B" designation [1] - The merger agreement with Yiteng Pharmaceutical was signed on September 13, 2024, and involves a reverse acquisition through a share swap [1] Group 2: Market Impact and Product Development - Jiahe Biotech's stock price increased by over 7% during trading, with a current increase of 4.9%, reaching HKD 3.21, and a trading volume of HKD 2.2008 million [1] - The company recently announced that its product, GB491 (Lairosili), has been included in the national medical insurance drug list, which is expected to enhance patient accessibility and reduce economic burdens [1] - The inclusion of GB491 in the insurance directory is anticipated to accelerate its commercialization process and market penetration, thereby boosting innovative returns [1]
嘉和生物-B现涨超4% 建议合并已完成 拟更名为“亿腾嘉和”并移除“B”标记